title: Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice.
abstract: Bone and lung metastases are responsible for the majority of deaths in patients with breast cancer. Following treatment of the primary cancer, emotional and psychosocial factors within this population precipitate time to recurrence and death, however the underlying mechanism(s) remain unclear. Using a mouse model of bone metastasis, we provide experimental evidence that activation of the sympathetic nervous system, which is one of many pathophysiological consequences of severe stress and depression, promotes MDA-231 breast cancer cell colonization of bone via a neurohormonal effect on the host bone marrow stroma. We demonstrate that induction of RANKL expression in bone marrow osteoblasts, following β2AR stimulation, increases the migration of metastatic MDA-231 cells in vitro, independently of SDF1-CXCR4 signaling. We also show that the stimulatory effect of endogenous (chronic stress) or pharmacologic sympathetic activation on breast cancer bone metastasis in vivo can be blocked with the β-blocker propranolol, and by knockdown of RANK expression in MDA-231 cells. These findings indicate that RANKL promotes breast cancer cell metastasis to bone via its pro-migratory effect on breast cancer cells, independently of its effect on bone turnover. The emerging clinical implication, supported by recent epidemiological studies, is that βAR-blockers and drugs interfering with RANKL signaling, such as Denosumab, could increase patient survival if used as adjuvant therapy to inhibit both the early colonization of bone by metastatic breast cancer cells and the initiation of the "vicious cycle" of bone destruction induced by these cells.
authors: Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States of America.
authors: J Preston
authors: JP
authors: Campbell
authors: Matthew R
authors: MR
authors: Karolak
authors: Yun
authors: Y
authors: Ma
authors: Daniel S
authors: DS
authors: Perrien
authors: S Kathryn
authors: SK
authors: Masood-Campbell
authors: Niki L
authors: NL
authors: Penner
authors: Steve A
authors: SA
authors: Munoz
authors: Andries
authors: A
authors: Zijlstra
authors: Xiangli
authors: X
authors: Yang
authors: Julie A
authors: JA
authors: Sterling
authors: Florent
authors: F
authors: Elefteriou
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D001859:Bone Neoplasms / Q000556:secondary*; D002465:Cell Movement; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000473:pathology*; D051379:Mice; D010006:Osteoblasts / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects; D015398:Signal Transduction; D017154:Stromal Cells / Q000166:cytology*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*
chemical_list: D000319:Adrenergic beta-Antagonists; D018343:Receptors, Adrenergic, beta-2; D011433:Propranolol